Whistler Conference Centre Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2017



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Immune Regulation in Autoimmunity and Cancer (D1)


Organizer(s) David A. Hafler, Vijay K. Kuchroo and Jane L. Grogan
March 26—30, 2017
Whistler Conference Centre • Whistler, British Columbia Canada
Discounted Abstract Deadline: Nov 29, 2016
Abstract Deadline: Jan 10, 2017
Scholarship Deadline: Nov 29, 2016
Discounted Registration Deadline: Jan 25, 2017

Sponsored by Abide Therapeutics Inc., BioLegend, Inc., Genentech, Inc., Juno Therapeutics, MorphoSys AG, OncoMed Pharmaceuticals, Inc., Pfizer Inc. and Roche. This activity was supported by an educational grant from Celgene Corporation.

Summary of Meeting:
While the importance of adoptive and innate immunity has been clear in the pathogenesis of human autoimmune disease resulting in a multitude of immune-based therapeutic approaches, the realization is now apparent that understanding immune evasion by cancer is central in developing curative treatments. This meeting will explore and contrast the underlying immune mechanisms resulting in autoimmunity and tumor evasion. The meeting is innovative in bringing together basic immunologists investigating mechanisms of tolerance with scientists exploring immune mechanisms of autoimmunity and cancer in both patients and experimental models. Thus, this Keystone Symposia meeting will cover the pathways in immunity and tolerance that lead to loss of immunological control, dysregulated immune responses and chronic inflammatory disease or tumor evasion. Presentations will include consideration of preclinical and clinical aspects of a diverse number of autoimmune and inflammatory diseases and cancer. Conference participants engaged in preclinical, translational and clinical research will hopefully engage in continuing conversations and collaborations which, over the long-term, will provide greater insights into the human immune response and allow us to reassess and further explore pathways that are driving autoimmune disease yet in opposition, lead to tumor evasion. Understanding checkpoints in autoimmunity and immune cell tolerance is important for delivering therapies to patients with autoimmune disease and cancer, and this meeting will provide a platform for the cross-pollination of clinical experience and experimental research. Attendees will have learned about the impact of targeted immune-based therapeutics on clinical outcome and, consequently, be able to widen their research scope accordingly.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Sunday, March 26 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 30 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 31 in order to fully experience the meeting.

SUNDAY, MARCH 26

16:00—20:00
Arrival and Registration

Grand Foyer
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Grand Foyer

MONDAY, MARCH 27

07:00—08:00
Breakfast

Sea to Sky B
08:00—09:00
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.

Sea to Sky C
* David A. Hafler, Yale University School of Medicine, USA

James P. Allison, University of Texas MD Anderson Cancer Center, USA
Cancer Immunotherapy

09:00—11:15
Tissue Micro-Immune Environments in Tumors and Autoimmune Tissue Inflammation
Meeting has ended...abstracts no longer viewable online.

Sea to Sky C
Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA
From the Clinic to the Lab: Investigating Response and Resistance Mechanisms to Immune Checkpoint Therapy

Coffee Break

Jennifer L. Gommerman, University of Toronto, Canada
Compartmentalization of B Cells During CNS Inflammation

* Jane L. Grogan, Genentech, Inc., USA
Immunoregulatory Roles of TIGIT and PVR-nectin Family in Tumors

Abigail E. Overacre, University of Pittsburgh, USA
Short Talk: Interferon-gamma drives Treg Functional Instability thereby Promoting Anti-Tumor Immunity

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Sea to Sky B
13:00—22:00
Poster Viewing

Sea to Sky B
14:30—16:30
Workshop 1: Effector T Cells

Sea to Sky C
* Thomas Korn, Technical University Munich, Germany

* Jane L. Grogan, Genentech, Inc., USA

June-Yong Lee, New York University School of Medicine, USA
Systemic and Local Functions of Serum Amyloid A (SAA) in Th17 Cell Pathogenicity

Jinju Lee, Kyoto University Graduate School of Medicine, Japan
Regulation of Th17 Expansion by PGE2-EP2/EP4 Signaling and its Clinical Implication

Pradip Nair, Biocon Research Limited, India
T Cell Activation and Differentiation to Th17 Cells is Modulated by a CD6 Domain 1 Antibody Itolizumab

Patricia Castillo, University of Pittsburgh, USA
Disrupted Enteric Th17 Signaling Exacerbates Autoimmune Inflammation

Michael Waterfield, University of California, San Francisco, USA
Characterization of a Novel Epigenetic Regulator Required for Th17 Differentiation

Mark S. Sundrud, The Scripps Research Institute, USA
The Xenobiotic Transporter Mdr1 Permits T Cell Adaptation to Mucosa-Associated Bile Acids in the Ileum

Geoffrey Alexander Smith, University of California, San Francisco, USA
IL-2RB Receptor Levels Tune T-Cell IL-2 Responses by Altering Signaling Dynamics in Different T Cell Subsets

Peter A. Morawski, NIAID, National Institutes of Health, USA
Brain Infiltrating CD8+ T Cells in Lupus-Prone Mice

16:30—17:00
Coffee Available

Grand Foyer
17:00—19:00
Basic Mechanisms of T Cell Tolerance
Meeting has ended...abstracts no longer viewable online.

Sea to Sky C
* Jeffrey A. Bluestone, University of California, San Francisco, USA
Treg Biology and Treatment in Autoimmune Diseases and Cancer

David A. Hafler, Yale University School of Medicine, USA
IFNgamma Identifies Dysfunctional Regulatory T Cells in Autoimmunity and Cancer

Alexander Y. Rudensky, HHMI/Memorial Sloan Kettering Cancer Center, USA
Regulatory T Cells in Cancer

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Sea to Sky B
19:30—22:00
Poster Session 1

Sea to Sky B

TUESDAY, MARCH 28

07:00—08:00
Breakfast

Sea to Sky B
08:00—11:00
Metabolic Regulation of T Cell Function in Cancer and Autoimmunity
Meeting has ended...abstracts no longer viewable online.

Sea to Sky C
* Erika L. Pearce, Max Planck Institute of Immunobiology and Epigenetics, Germany
How Metabolism Influences CD8 Cells in Cancer

Douglas R. Green, St. Jude Children's Research Hospital, USA
Cell Death and Resuscitation: To the Edge of Necroptosis and Back

Coffee Break

Jens Titze, Vanderbilt University, USA
Rethinking Sodium Metabolism

Tomokazu Sumida, Yale School of Medicine, USA
Short Talk: Beta-catenin Links High Salt and Proinflammatory Signature in Treg

Seungho Lee, Yonsei University, South Korea
Short Talk: Exploration of Tumor Microenvironment and Metabolism using Tumor Infiltrating Lymphocytes and FDG-PET CT

11:00—17:00
On Own for Lunch

11:00—13:00
Poster Setup

Sea to Sky B
13:00—22:00
Poster Viewing

Sea to Sky B
14:30—16:30
Workshop 2: Tregs in Autoimmunity and Cancer

Sea to Sky C
* Alexander Y. Rudensky, HHMI/Memorial Sloan Kettering Cancer Center, USA

* Ana Carrizosa Anderson, Harvard Medical School, USA

Liliana Elisa Lucca, Yale University, USA
PD-1 Marks Dysfunctional Regulatory T Cells in Malignant Gliomas

Maran L. Sprouse, Baylor College of Medicine, USA
High CD5 Expression is a Marker of Functional Regulatory T Cells in Autoimmunity

Catherine Konopacki, Memorial Sloan Kettering Cancer Center, USA
Foxp1 Is a Foxp3 Binding Partner that Contributes to Regulatory T Cell Stability and Function

Allison L. Bayer, University of Miami School of Medicine, USA
Immunomodulation Requirements for Treg Immunotherapy for Autoimmune Diabetes

Danbee Ha, Osaka University, Japan
ADCC-Mediated in vitro Depletion of Human Treg Cells by Anti-CTLA-4 mAb Enhances CD8+ T Cell Responses against Self/Tumor Antigens

David Bauche, Merck, USA
Foxp3+ Regulatory T Cells Prevent from ILC3-Driven Colitis

Wenxian Fu, University of California, San Diego, USA
A Tissue-Resident Macrophage Specific Coinhibitory Molecule Promotes Regulatory T Cell Differentiation and Stability

Dana Catherine Gilmore, University of Chicago, USA
Identification of Natural Peptide Epitopes Recognized by Regulatory T Cells

16:30—17:00
Coffee Available

Grand Foyer
17:00—19:00
Effector T Cell Dysfunction: Surface Receptors in Autoimmunity vs. Cancer
Meeting has ended...abstracts no longer viewable online.

Sea to Sky C
* Arlene H. Sharpe, Harvard Medical School, USA
Role of Coinhibitory Receptors in Controlling Effector T Cells

E. John Wherry, University of Pennsylvania, USA
Molecular Basis of T Cell Exhaustion: Insights for Immunotherapy

Ana Carrizosa Anderson, Harvard Medical School, USA
T Cell Dysfunction: From Co-Inhibitory Receptors to Molecular Programs

Christopher E. Rudd, University of Montreal, Canada
Short Talk: A Next Generation Approach using Small Molecules to Inhibit PD-1 Transcription Is as Effective as Anti-PD-1/PL1 Biologics in Immunotherapy

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Sea to Sky B
19:30—22:00
Poster Session 2

Sea to Sky B

WEDNESDAY, MARCH 29

07:00—08:00
Breakfast

Sea to Sky B
08:00—11:00
Innate Regulation of Autoimmunity and Cancer
Meeting has ended...abstracts no longer viewable online.

Sea to Sky C
Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, USA
Role of Dendritic Cells and NK Cells in Mediating Anti-Tumor Responses

Federica Sallusto, University of Italian Switzerland, Switzerland
Autoreactive T Cells in Narcoleptic Patients

Coffee Break

* Carla V. Rothlin, Yale University, USA
Innate Immune Checkpoints in Anti-Tumor Immunity

Mark J. Smyth, QIMR Berghofer Medical Research Institute, Australia
Barriers to NK Cell Control of Cancer

Keiji Hirota, Institute for Frontier Life and Medical Sciences, Kyoto University, Japan
Short Talk: An Inflammatory Cellular Network of Autoimmune Th17 Cells, GM-CSF-Producing ILCs and Synoviocytes in the Development of Autoimmune Arthritis

11:00—17:00
On Own for Lunch

11:00—13:00
Poster Setup

Sea to Sky B
13:00—22:00
Poster Viewing

Sea to Sky B
14:30—16:30
Workshop 3: T Cell Tolerance, Exhaustion and Dysfunction in Autoimmunity and Cancer

Sea to Sky C
* Kenneth Smith, University of Cambridge, UK

Rachel S. Friedman, National Jewish Health and University of Colorado, Denver, USA
MerTK Mediates T Cell Tolerance in the Pancreatic Islets during Type 1 Diabetes

Yemsratch T. Akalu, Yale University School of Medicine, USA
An eMERging Target in Cancer Immunotherapy

Rachael Bashford-Rogers, University of Cambridge, UK
Using High-Throughput Sequencing to Reveal Insights into the Relationship between B-Cell Repertoire, Phenotype and Function in Health, Cancer and Autoimmune Disease

David M. Sansom, University College London Medical School, UK
CTLA-4 Mutations from Patients with Immune Dysregulation Syndromes Inform our Understanding of CTLA-4 Function

Jennifer Lori Blanchfield, Emory University, USA
MOG-Specific Tolerance Mechanisms Limit Autoimmune Demyelinating Disease following Bacterial Delivery of MOG Epitope

John R. Sedy, Sanford Burnham Prebys Medical Discovery Institute, USA
Cancer Mutations Targeting TNFRSF14 alter Microenvironment Checkpoint Interactions to Limit Tumor Clearance by Cytotoxic Cells

Greg M. Delgoffe, University of Pittsburgh, USA
Defects in Mitochondrial Biogenesis and Oxidative Function Underlie Tumor-Infiltrating T Dysfunction

16:30—17:00
Coffee Available

Grand Foyer
17:00—19:00
B Cell Regulation of Autoimmunity
Meeting has ended...abstracts no longer viewable online.

Sea to Sky C
* Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland
Mechanisms of Antibody Diversification

Kenneth Smith, University of Cambridge, UK
Predicting and Explaining the Future: A New Biology of Clinical Outcome in Autoimmunity?

Alicia Gonzalez-Martin, The Scripps Research Institute, USA
Short Talk: MicroRNA Control of B Cell Tolerance and Autoimmunity

Bonnie Huang, NHGRI, National Institutes of Health, USA
Short Talk: Dissecting T Follicular Helper Cell Development in vivo using CRISPR

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Sea to Sky B
19:30—22:00
Poster Session 3

Sea to Sky B

THURSDAY, MARCH 30

07:00—08:00
Breakfast

Sea to Sky B
08:00—11:15
Ten Years of Discovery of Th17 Cells: From Bench to Bedside
Meeting has ended...abstracts no longer viewable online.

Sea to Sky C
* Vijay K. Kuchroo, Brigham and Women's Hospital, Harvard Medical School, USA
Transcriptional Networks in Development of Th17 Cells

Dan R. Littman, HHMI/New York University School of Medicine, USA
Th17 Cells in the Gut Homoeostasis

Coffee Break

Thomas Korn, Technical University Munich, Germany
Trans-presentation of IL-6 by Dendritic Cells - A Novel Mode of IL-6 Signaling – Is Required for the Priming of Pathogenic TH17 Cells in vivo

Daniel J. Cua, Merck Research Laboratories, USA
The IL-23-Th17 Immune Axis: From Mechanisms to Therapeutic Testing

Dhavalkumar D. Patel, Inflazome, Switzerland
Therapeutic Targeting of Th17 Cells in Autoimmune Diseases

11:15—17:00
On Own for Lunch

16:30—17:00
Coffee Available

Grand Foyer
17:00—18:45
Systems Biology Approaches to Understanding Tolerance in Cancer and Autoimmunity
Meeting has ended...abstracts no longer viewable online.

Sea to Sky C
* Frank Oliver Nestle, Sanofi, USA
Deciphering the Rules of Engagement of Tissue Immunity

Alex Marson, University of California, San Francisco, USA
Decoding T Cell Circuitry

Meromit Singer, Broad Institute, USA
Short Talk: Identification and Validation of a Gene Module Specific for T Cell Dysfunction in Tumor via Population and Single-Cell Transcriptomics

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.

Sea to Sky C
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Sea to Sky B
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Sea to Sky B

FRIDAY, MARCH 31

 
Departure


*Session Chair †Invited, not yet responded.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Abide Therapeutics Inc. BioLegend, Inc.

This activity was supported by an educational grant from Celgene Corporation

Genentech, Inc.
Juno Therapeutics MorphoSys AG
OncoMed Pharmaceuticals, Inc. Pfizer Inc.
Roche
 

We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge additional support for this conference from:

CEDARLANE

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Genentech, Inc.


Novartis Institutes for BioMedical Research


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

BioMed Central Ltd

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Assistant Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676